Out of stock
Mucosamin Rectal Gel is indicated in the treatment of rectal mucositis caused by radiation treatment for cancer of the pelvic area, and is also indicated in rectal mucositis caused by chemotherapy, or combined treatments of chemotherapy and radiotherapy
As of July the 1st 2021 the rules on VAT for EU sales will be changing. For orders less than £135 (€150) we will display the total price inclusive of the VAT rate. For orders above this amount, you will not be charged VAT and you will be required to pay this when your goods arrive in your country. Read more on the new rules here.
Mucosamin Rectal Gel is a CE marked medical device that acts as protective layer when applied topically to the rectal mucosa.
Mucosamin Rectal Gel creates a protective layer over erythematous or ulcerated mucosa.
Mucosamin Rectal Gel can be used to help preserve the mucosa trophism in order to prevent the onset of rectal mucositis.
Mucosamin Rectal Gel creates a protective layer over erythematous or ulcerated mucosa, thereby providing a rapid reduction in burning, pain, and symptomatology deriving from neurological damage in proctitis caused by radiotherapy and/or chemotherapy of pelvic tumours.
The hyaluronic acid and amino acids in Mucosamin® Rectal Gel help to promote a regenerative stimulus of collagen and epithelial tissue, and therefore help to regenerate the mucosa.
The direct effects of radiation on the bowel mucosa can cause almost every patient to have some manifestation of acute radiation-induced injury of the GI tract in the form of burning pain sensations, abdominal cramping, tenesmus, urgency, bleeding, diarrhoea and incontinence.
Radiotherapy initially causes mucosal changes characterised by inflammation or cell death, but subsequently persistent cytokine activation in the submucosa leads to chronic effects such as progressive ischaemia, fibrosis and loss of stem cells. These ischaemic and fibrotic changes potentially cause chronic impairment of GI physiological functions. Acute changes in GI physiology can occur in any part of the GI tract that is exposed to radiotherapy, leading to clinical or subclinical symptoms.
Symptoms of acute radiation proctitis include burning pain sensations, diarrhoea, nausea, cramps, tenesmus, urgency, mucous discharge and minor bleeding. Acute radiation proctitis appears oedematous, beefy red, and may have ulceration or sloughing. Microscopically, there is a loss or distortion of the microvillus architecture with hyperaemia, oedema and ulceration. Acute radiation proctitis is caused by the death of rectal mucosal cells, and is confined to the lower 25cm of the large intestine.
Cytotoxic chemotherapy agents have a direct effect on the GI mucosa, exerting chemotherapeutic damage to the epithelium, causing inflammation, oedema, ulceration and atrophy. The degree of damage to the mucosa, submucosa and GI stem cells may play a role in the development of chronic problems. In addition, chemotherapy increases the sensitivity of non-cancerous tissues to damage from radiotherapy.
GI symptoms are the most common of all the chronic physical side effects of cancer treatment, and have the greatest impact on quality of life. Yet, the prevalence of GI side effects following cancer treatment is reported to be underestimated.
You can view how to use the product here.
Before applying the product, clean the affected area thoroughly. Remove the cap, insert the spout applicator and press the sides to dispense the gel.
If necessary, before inserting the applicator, take a small portion of the gel and lubricate the applicator in order to facilitate its insertion by reducing the possible tenderness of the area. Then insert the spout of the applicator and pressing the sides firmly, applying the entire contents of the gel evenly.
The vial is single-use only.